FORMULIERUNGEN VON BENDAMUSTIN

European patent · EP4360621 · In force

Register entry

Publication number
EP4360621
Application number
EP23218288
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 15, 2013
Published
May 1, 2024
Granted
May 6, 2026
Protection ends at the latest
Mar 14, 2033
Next annual fee due
Mar 31, 2027
IPC classes
A61K 31/4184 (2006.01)
A61K 47/10 (2017.01)
A61K 9/00 (2006.01)
A61K 47/02 (2006.01)
A61K 47/20 (2006.01)
Priority
US 201261613173 P 20.03.2012
US 201261669889 P 10.07.2012
Divided from
EP13764989
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 6, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 06.05.2026

Parties

Holder

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard Suite 315, Woodcliff Lake, NJ 07677, US

Inventor

SUNDARAM, Srikanth

Somerset, 08873, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.